Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Cytosolve Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to a distinct examiner and a distinct art unit. The company's current prosecution activity is focused on this one pending action, which constitutes its entire active workload before the office. This narrow focus indicates that the company's immediate biotechnology-related patenting efforts are concentrated in a single application, making the outcome of this 1 pending office action the primary indicator of its current success in this technology area.
NEGIN, RUSSELL SCOTT is the busiest examiner for this portfolio, currently overseeing 1 pending office action. This individual is responsible for the active prosecution currently active for the company. The involvement of a distinct art unit suggests that the pending application is being reviewed within a specific technical niche of the biotechnology field. Since there is only a single distinct examiner for the 1 pending office action, the company's prosecution strategy must be tailored specifically to the examination style and technical requirements of this official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEGIN, RUSSELL SCOTT | 1 | 55.9% | +34.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18474019 | SYSTEM AND METHOD FOR QUANTIFICATION OF SYNERGISTIC EFFECTS OF MULTI-COMBINATION COMPOUNDS | NEGIN, RUSSELL SCOTT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18474019 | SYSTEM AND METHOD FOR QUANTIFICATION OF SYNERGISTIC EFFECTS OF MULTI-COMBINATION COMPOUNDS | NEGIN, RUSSELL SCOTT | — |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18474019 | SYSTEM AND METHOD FOR QUANTIFICATION OF SYNERGISTIC EFFECTS OF MULTI-COMBINATION COMPOUNDS | NEGIN, RUSSELL SCOTT | 1686 | §101§103 | Non-Final OA | — | Pending | Sep 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCytosolve Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Russell Scott Negin has the most, with 1 of Cytosolve Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
